Home/Filings/4/0001104659-21-003134
4//SEC Filing

Wood Gavin 4

Accession 0001104659-21-003134

CIK 0001621227other

Filed

Jan 10, 7:00 PM ET

Accepted

Jan 11, 9:03 PM ET

Size

8.6 KB

Accession

0001104659-21-003134

Insider Transaction Report

Form 4
Period: 2021-01-11
Wood Gavin
Chief Financial Officer
Transactions
  • Award

    Option to purchase Ordinary Shares

    2021-01-11+242,712242,712 total
    Exercise: $0.00Exp: 2031-01-11Ordinary Shares (242,712 underlying)
  • Award

    Option to purchase Ordinary Shares

    2021-01-11+1,086,8161,086,816 total
    Exercise: $1.03Exp: 2031-01-11Ordinary Shares (1,086,816 underlying)
Footnotes (4)
  • [F1]The exercise price was converted from GBP0.76 based on an exchange rate of U.S.$ 1.358422 to GBP1.00. The actual exercise price will be the pounds sterling amount.
  • [F2]Exercisable as to 271,704 Ordinary Shares on January 11, 2022 and will be exercisable as to the remainder in monthly installments of 22,638 Ordinary Shares on the eleventh of each month from February 11, 2022 through December 11, 2024 and 22,782 Ordinary Shares on January 11, 2025.
  • [F3]The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.358422 to GBP1.00. The actual exercise price will be the pounds sterling amount.
  • [F4]Exercisable as to 60,678 Ordinary Shares on January 11, 2022 and will be exercisable as to the remainder in annual installments of 60,678 Ordinary Shares on the eleventh of each January from January 11, 2023 through January 11, 2025.

Issuer

Adaptimmune Therapeutics PLC

CIK 0001621227

Entity typeother

Related Parties

1
  • filerCIK 0001577539

Filing Metadata

Form type
4
Filed
Jan 10, 7:00 PM ET
Accepted
Jan 11, 9:03 PM ET
Size
8.6 KB